Abstracts

979 – Epigenetic Changes With T. gondii in Brains of People With HIV and Their Possible Link to Gliomas

Background Toxoplasma gondii, a zoonotic parasite, poses risks for people with HIV (PWH). Although its clinical impact is minimal in immunocompetent hosts, U.S. seroprevalence studies show a 20-30% infection rate. The parasite forms bradyzoites in brain and muscle tissue that can reactivate when CD4+ T cell counts drop in PWH, leading to severe disease. Additionally,…

987 – Sleep Patterns in South African Pregnant Women Living With HIV on Dolutegravir: A Prospective Study

Background Adverse sleep patterns are common in people living with HIV generally and have been associated specifically with dolutegravir (DTG) use in studies from high-income countries. Pregnancy and obesity are both known to adversely affect women’s sleep, however there are few data assessing the impact of HIV/DTG on sleep patterns among pregnant women in Africa.…

1006 – Social Determinants Associated With Recent HIV Infection in Treatment-Naive Pregnant Women in Malawi

Background Young women in sub-Sahara Africa face a high risk of acquiring HIV. Antiretroviral therapy (ART) is prioritized for pregnant women with HIV to treat the infection and prevent transmission to newborns. Assessing recency of infection in women who initiated ART during pregnancy and the associated social determinants are pivotal to monitor the epidemic in…

1018 – Population PK and CYP3A Inhibition Capacity of Ritonavir in Pregnancy: A Model-Based Meta-Analysis

Background Ritonavir (RTV), a strong CYP3A inhibitor, is widely used as a pharmacokinetic (PK) enhancer to increase exposure to HIV-1 protease inhibitors (PIs) and more recently the SARS CoV-2 PI nirmatrelvir.  Pregnancy-related changes in RTV disposition and boosting capacity have not been systematically assessed which may inform RTV dosing in pregnancy for future emerging infectious…

1001 – Impact of Gestational Diabetes on Pregnancy Outcomes in South African Women Living With HIV

Background The prevalence of gestational diabetes (GDM) is increasing globally, including in settings where HIV is prevalent. GDM is associated with pregnancy loss and large-for-gestational age (LGA) deliveries but there are no data on whether these associations are altered by maternal HIV and/or antiretroviral therapy. Methods The ORCHID study enrolled pregnant women with HIV (WLH)…

1013 – ART Reverses Negative Natural Selection of HIV Disease-Linked HLA-I in KwaZulu-Natal, South Africa

Background HLA is the most polymorphic region in the human genome, as the differential HLA-dependent impact of certain infections, inflammatory conditions, autoimmune diseases and cancers drive its evolution. However, clear examples of infection-driven evolution are rare. Here, we investigated antenatal cohorts in KwaZulu-Natal (KZN), South Africa, the region most severely affected by the global HIV…

958 – Genetics of Plasma Rifapentine Clearance During Pulmonary Tuberculosis Treatment in Study 31/A5349

Background Optimizing rifapentine (RPT) dosing is critical for improving tuberculosis (TB) treatment response. Study 31/A5349 (NCT02410772) compared two 4-month RPT-containing regimens — one with and one without moxifloxacin (MFX) — to the standard 6-month regimen. A key determinant of unfavorable TB outcomes in this trial was RPT exposure, with large interindividual variability. We hypothesized that…

985 – Genome-Wide Association With Postpartum Weight Change in Mothers on DTG or EFV in DolPHIN-2

Background DolPHIN-2 (NCT 03249181) randomised mothers initiating ART in late pregnancy to efavirenz (EFV)- or dolutegravir (DTG) based regimens. We previously reported no significant differences between arms in weight change post-delivery to 48w postpartum (PP), but observed heterogeneity with numerically greater weight gain in women from South Africa.  Here, we undertook a genome-wide association study…

971 – Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy

Background Tuberculosis preventive therapy (TPT) is a key intervention for tuberculosis (TB) elimination. The introduction of long acting (LA) TPT has the potential to enhance adherence, minimize treatment interruptions, improve completion rates, and extend protection against tuberculosis. Methods We conducted a cross-sectional in-person survey among patients in two high-burden TB countries to evaluate preferences, and concerns…